Skip to content

Study · Animal study (in vivo) · rat · 2001

4 results

Therapy effect of antiulcer agents on new chronic cysteamine colon lesion in rat.

Sikiric P, Seiwerth S, Aralica G, Perovic D, Staresinic M, Anic T, Gjurasin M, Prkacin I, Separovic J, Stancic-Rokotov D, Lovric-Bencic M, Mikus D and 13 more

Show all authors

Turkovic B, Rotkvic I, Mise S, Rucman R, Petek M, Ziger T, Sebecic B, Ivasovic Z, Jagic V, Komericki L, Balen I, Boban-Blagaic A, Sjekavica I

Journal of physiology, Paris1 Jan 2001Cited by 16 (Europe PMC)

PMID11595451 (opens in a new tab)DOI10.1016/s0928-4257(01)00039-0 (opens in a new tab)PepBankPUB-11595451
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with chronic cysteamine colon lesions, BPC‑157 markedly mitigated the lesions, as did ranitidine, omeprazole, atropine, methylprednisolone and sulphasalazine.

    In plain wordsIn rats with long-lasting colon lesions caused by cysteamine, BPC‑157 clearly reduced the lesions.

    Peptide
    BPC-157
    Outcome
    DecreaseChronic cysteamine colon lesions
    Study

    ratn: not reported in source

    chronic cysteamine colon lesion
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 µg/kg or 10 ng/kg · intragastric, intraperitoneal or intrarectalAs given in this study (rat).

    Source sentences

    Summary
    Regularly, cysteamine colon lesions were markedly mitigated by ranitidine (10), omeprazole (10), atropine (10), methylprednisolone (1), sulphasalazine (50; mg/kg), pentadecapeptide BPC 157 (PL-10, PLD-116; 10 microg or 10 ng/kg).
    1 context sentence
    Summary · context
    Thus, the further focus was on the protracted effect of cysteamine challenge (400 mg/kg b.w. i.r.) and therapy influence in chronic experiments in female rats.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In female rats, a 1-week once-daily regimen of BPC‑157 started 1 month after cysteamine reversed the protracted colon injury.

    In plain wordsIn female rats, one week of daily BPC‑157 started a month after the injury reversed the long-lasting colon damage.

    Peptide
    BPC-157
    Outcome
    DecreaseProtracted colon injury, 1-week regimen after 1 month
    Study

    ratn: not reported in source

    chronic cysteamine colon lesion
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 µg/kg or 10 ng/kg · intragastric, intraperitoneal or intrarectal · 1 week, once daily, started 1 month after cysteamineAs given in this study (rat).

    Source sentences

    Summary
    the therapy [BPC 157 (PL-10, PLD-116 (10.0 microg or 10.0 ng/kg; i.g., i.p., i.r.), ranitidine, omeprazole, atropine, methylprednisolone, sulphasalazine (i.p.)] reversed the protracted cysteamine colon injury: the 1 week-regimen (once daily application) started after 1 month post-cysteamine
    1 context sentence
    Summary · context
    Thus, the further focus was on the protracted effect of cysteamine challenge (400 mg/kg b.w. i.r.) and therapy influence in chronic experiments in female rats.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In female rats, a 2-week once-daily regimen of BPC‑157 started 3 months after cysteamine reversed the protracted colon injury.

    In plain wordsIn female rats, two weeks of daily BPC‑157 started three months after the injury reversed the long-lasting colon damage.

    Peptide
    BPC-157
    Outcome
    DecreaseProtracted colon injury, 2-week regimen after 3 months
    Study

    ratn: not reported in source

    chronic cysteamine colon lesion
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 µg/kg or 10 ng/kg · intragastric, intraperitoneal or intrarectal · 2 weeks, once daily, started 3 months after cysteamineAs given in this study (rat).

    Source sentences

    Summary
    the therapy [BPC 157 (PL-10, PLD-116 (10.0 microg or 10.0 ng/kg; i.g., i.p., i.r.), ranitidine, omeprazole, atropine, methylprednisolone, sulphasalazine (i.p.)] reversed the protracted cysteamine colon injury
    2 context sentences
    Summary · context
    as well as the 2 weeks-regimen (once daily application), which started after 3 months.
    Summary · context
    Thus, the further focus was on the protracted effect of cysteamine challenge (400 mg/kg b.w. i.r.) and therapy influence in chronic experiments in female rats.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In female rats, reappearance of cysteamine colon lesions after stopping therapy was markedly antagonized in BPC‑157 rats, whereas lesions may reappear in the sulphasalazine group.

    In plain wordsIn female rats, colon lesions came back much less after BPC‑157 was stopped than after sulphasalazine was stopped.

    Peptide
    BPC-157
    Outcome
    DecreaseReappearance of colon lesions after stopping therapy
    Study

    ratn: not reported in source

    chronic cysteamine colon lesion
    Comparator
    Sulphasalazine group
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 µg/kg or 10 ng/kg · intragastric, intraperitoneal or intrarectal · 2 weeks, then 3 weeks without therapyAs given in this study (rat).

    Source sentences

    Summary
    These cysteamine lesions may reappear after stopping therapy (after stopping therapy for 3 weeks at the end of 2-weeks regimen started in 3 months-cysteamine female rats) in sulphasalazine group, while this reappearance is markedly antagonized in pentadecapeptide BPC 157 (PL-10, PLD-116)-rats (cyste…
    1 context sentence
    Summary · context
    Thus, the further focus was on the protracted effect of cysteamine challenge (400 mg/kg b.w. i.r.) and therapy influence in chronic experiments in female rats.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.